載入...
In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
The biopharmaceutical industry has become increasingly focused on developing biosimilars as less expensive therapeutic products. As a consequence, the regulatory approval of 2 antibody-drug conjugates (ADCs), Kadcyla® and Adcetris® has led to the development of biosimilar versions by companies locat...
Na minha lista:
| 發表在: | MAbs |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5058630/ https://ncbi.nlm.nih.gov/pubmed/27380163 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1204502 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|